Galectin Therapeutics Inc (GALT) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001133416

Market Cap 203.08 Mn

P/B -1.62

P/E -5.42

P/S 0.00

ROIC (Qtr) 3,992.88

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 122.28 Mn

Debt/Equity (Qtr) -0.98

About

Retained earnings of (426.98M) represent substantial 3.41x of equity (125.30M), indicating strong internal capital generation.
Robust R&D investment of 23.47M at 4.13x of SG&A 5.68M demonstrates strong commitment to innovation and future growth.
Cash position of 11.53M fully covers payables of 5.39M by 2.14x, showing strong vendor relationship management.

Investment activities of 0 provide weak support for R&D spending of 23.47M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
The company's operating cash flow of (30.62M) shows concerning coverage of stock compensation expenses of 2.05M, with a -14.91 ratio indicating potential earnings quality issues.
Operating earnings of (30.19M) show weak coverage of depreciation charges of 22000, with a -1372.18 ratio indicating high capital intensity and potential reinvestment needs.
Free cash flow of (30.62M) represents just -2.78x of debt issuance 11M, suggesting concerning reliance on leverage rather than internal cash generation for growth.
Tangible assets of 12.87M provide limited backing for working capital of (123.72M), which is -0.10x, suggesting increased operational risk in market downturns.

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,446.17 Bn	-1,569.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	439.23 Bn	6,407.40	88.33	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	120.62 Bn	32.82	10.29	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	84.40 Bn	18.44	5.92	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	56.13 Bn	1,288.39	17.49	3.21 Bn
6	ARGX	Argenx Se	47.89 Bn	31.79	24,973.95	-
7	BNTC	Benitec Biopharma Inc.	42.45 Bn	-1,015.00	0.00	0.00 Bn
8	INSM	INSMED Inc	32.67 Bn	-27.60	73.08	0.74 Bn

Current Valuation	Value	Ind Avg
EV to Assets EV to Assets	24.08	12.96
EV to Cash from Ops. EV/CFO	-10.12	23.73
EV to Debt EV to Debt	2.53	772.65
EV to EBIT EV/EBIT	-10.26	-11.30
EV to EBITDA EV/EBITDA	-10.64	7.11
EV to Free Cash Flow [EV/FCF] EV/FCF	-10.12	22.12
EV to Market Cap EV to Market Cap	1.53	68.89
EV to Revenue EV to Revenue	0.00	199.70
Price to Book Value [P/B] P/B	-1.62	22.62
Price to Earnings [P/E] P/E	-5.42	-12.30

Dividend Metrics	Value	Ind Avg
Dividend Coverage Ratio Div Coverage (Qtr)	-269.37	-12.02
Dividend Payout Ratio % Div Payout % (Qtr)	0.00	0.17
Dividend per Basic Share Div per Share (Qtr)	0.00	0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr)	0.00	-0.15
Interest Coverage Int. cover (Qtr)	-4.24	857.11

Growth Metrics	Value	Ind Avg
Capex Growth (1y) % Capex 1y % (Qtr)	0.00	-27.24
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr)	-57.41	747.06
Dividend Growth (1y) % Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr)	25.30	-48.21
EBITDA Growth (1y) % EBITDA 1y % (Qtr)	26.32	-2.09
EBIT Growth (1y) % EBIT 1y % (Qtr)	25.30	-57.79
EBT Growth (1y) % EBT 1y % (Qtr)	17.25	-14.35
EPS Growth (1y) % EPS 1y % (Qtr)	19.18	-30.88
FCF Growth (1y) % FCF 1y % (Qtr)	9.07	-32.51
Gross Profit Growth (1y) % Gross Profit Growth (1y) %	0.00	227.96

Liquidity Ratios	Value	Ind Avg
Asset Utilization Ratio Asset Util Ratio (Qtr)	0.00	0.14
Cash Payout Ratio Cash Payout (Qtr)	0.00	0.00
Cash Ratio Cash Ratio (Qtr)	0.08	3.79
Current Ratio Curr Ratio (Qtr)	0.09	7.23
Debt to Equity Ratio Debt/Equity (Qtr)	-0.98	0.42
Interest Cover Ratio Int Coverage (Qtr)	-4.24	857.11
Times Interest Earned Times Interest Earned (Qtr)	-4.24	857.11

Profitability	Value	Ind Avg	Percentile
EBITDA Margin % EBITDA Margin %	0.00	-18,509.94
EBIT Margin % EBIT Margin %	0.00	-18,862.18
EBT Margin % EBT Margin %	0.00	-19,783.19
Gross Margin % Gross Margin %	0.00	-8.62
Net Profit Margin % Net Profit Margin %	0.00	-19,732.60